Coherus Oncology, Inc. (CHRS) Capital expenditures 2016–2023
Coherus Oncology, Inc. (CHRS) annual capital expenditure history — cash spent on property, plant and equipment, per SEC filings.
$286,000FY2023 · since FY2016: $6.5M → $286,000
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | $286,000 | -86.0% |
| FY2022 | $2.0M | +58.2% |
| FY2021 | $1.3M | -82.2% |
| FY2020 | $7.2M | +296.9% |
| FY2019 | $1.8M | +130.9% |
| FY2018 | $789,000 | -82.7% |
| FY2017 | $4.6M | -29.8% |
| FY2016 | $6.5M | — |
Capital expenditures are shown as the positive cash amount spent, as reported on the cash-flow statement.
Source: SEC XBRL filings · For reference only · Not investment advice